Immatics is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell redirecting immunotherapies for the treatment of cancer. The company combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response against these targets.

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

COM:IMMATICS

Immatics

Last Close

7.58

22/11 17:59

Market Cap

918.92M

Beta: -

Volume Today

225.17K

Avg: -

market

industry

website

crunchbase

ipo date

peer of

competitor of

Metrics